Shares rise and fall at the behest of this agency, his heart fell on two stocks, disappointment with one, know the names of the stocks.

Goldman Sachs is a global agency and brokerage firm, on which every indicator of the stock market works. The stock that this agency raises its rating tends to rise rapidly. On the contrary, if the rating of any stock goes down, it starts to fall. The same Goldman Sachs recently issued two buy and one sell recommendations.

The brokerage has revised its target prices for Syngene International Ltd and Neuland Laboratories Ltd. Syngene’s target price has been increased by 20% to Rs 875 while Newland’s target price has been increased by 46% to Rs 9,100. On Friday, the stock of Syngene closed at Rs 749.05 on the NSE, while the stock of Newland Labs closed at Rs 6,665.40. At the same time, brokerage firm Goldman Sachs has advised Lars Labs Limited to sell. The firm has said that the share will fall by 23% to Rs 350. Its closing rate on Friday was Rs 441.90.

Also Read – This Tata Group company will pay a dividend of Rs 28 per share, increase in profit

Triple profit potential
It is worth noting that Goldman Sachs has recently increased its coverage in the India CRO/CDMO sector. In view of this, Indian companies are becoming important in the global pharmaceutical supply chain. They expect India’s global market share to grow by 30bps in small CDMOs and 70bps in CROs by FY28. In the same situation, this profit can be tripled.

Why are Syngene and Newland on the radar?
Syngene is the country’s largest integrated CRAMS/CRDMO, serving various sectors including pharmaceuticals, biotechnology and consumer goods. Goldman expects Syngene to benefit significantly from the China+1 trend due to its end-to-end service capabilities. Despite short-term macro challenges in CY24, a number of catalysts are expected including improvement in biotech funding, ramp-up of manufacturing plants and securing new contracts. This becomes especially important amid anti-China sentiment. Due to the implementation of the US Biosecure Act, the company can achieve better profitability.

Also Read: Price Rs 3 3 Years Back, Now Crosses Rs 963, Profit Hits Record High

Newland Labs develops APIs. Along with changes in CDMO services, it has added many new features to its offering. Despite growth challenges in FY25 due to high base, Goldman Sachs sees a number of opportunities for the company, including improved biotech funding, new capacity at Unit-3 to be commissioned in late FY25 and FY26/27 includes commercialization of a large molecule. Passage of the US Biosecure Act could also provide significant benefits.

(Disclaimer: The stock mentioned here is based on the advice of the brokerage houses. If you want to invest in any of them, consult a certified investment advisor first. News 18 of your profit or loss. shall not be liable.)

Tags: money making tips, Stock market, Stock market, Stock tips